160358-05-4

Upstream product

• 107-10-8 propylamine 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 179557-18-7 1-benzyl-4-[N-propyl-N-(3-nitro-2-pyridinyl)amino]piperidine 
• 179556-67-3 1-benzyl-4-(N-propyl-N-(3-cyano-2-pyridinyl)amino)piperidine 
• 675136-96-6 N-(piperidin-4-yl)dipropylamine 
• 1259401-76-7 N-(1-benzylpiperidin-4-yl)dipropylamine 
• 179557-25-6 1-benzyl-4-[N-propyl-N-(3-(1,1-dimethylethylamino)-2-pyridinyl)amino]-piperidine 
• 179557-22-3 N²-(1-Benzyl-piperidin-4-yl)-N³-isopropyl-N²-propyl-pyridine-2,3-diamine 
• 179557-19-8 1-benzyl-4-[N-propyl-N-(3-amino-2-pyridinyl)amino]piperidine 
• 179556-68-4 1-benzyl-4-(N-propyl-N-(3-acetyl-2-pyridinyl)amino)piperidine 
• 179556-69-5 1-benzyl-4-(N-propyl-N-(3-ethyl-2-pyridinyl)amino)piperidine 

Relevant academic research and scientific papers

Targeting delavirdine/atevirdine resistant HIV-1: Identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors

A novel class of bis(heteroaryl)piperazine (BHAP) analogs which possesses the ability to inhibit NNRTI (non-nucleoside reverse transcriptase inhibitor) resistant recombinant HIV-1 reverse transcriptase (RT) and NNRTI resistant variants of HIV-1 has been identified via targeted screening. Further investigation of the structure-activity relationships of close congeners of these novel (alkylamino)piperidine BHAPs (AAP-BHAPs) led to the synthesis of several compounds possessing the desired phenotype (e.g., activity against recombinant RTs carrying the Y181C and P236L substitutions). Further structural modifications were required to inhibit metabolism and modulate solubility in order to obtain compounds with the desired biological profile as well as appropriate pharmaceutical properties. The AAP-BHAPs with the most suitable characteristics were compounds 7, 15, and 36.

With anti-HIV active 3 - amino propionic acid piperidine amide compound, synthetic method and use

The invention relates to a 3-aminopropionic acid piperidine amide compound as shown in formula I, and its pharmaceutically acceptable salts or solvates, wherein the substituents are defined in claims; the invention also relates to a preparation method of the compound, pharmaceutical compositions containing the compound, the salts or solvates, and applications in preparation of drugs for treating HIV infection related diseases and symptoms.

Alkyl substituted piperadinyl and piperazinyl anti-AIDS compounds

Anti-AIDS compounds of formula (I) STR1 wherein R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification and R8 is alkyl of substituted alkyl.